3.18.2008

"Patients are unaware that they can return to the county hospital pharmacies or that any money can be saved on their medications."

Important news for our clients. Of course, if you've worked at all in this population, you'll pretty much know this already, but there are still many who don't, so the more its spread, the more it'll actually be utilized effectively....
Providing Medications for Low-Income and Indigent Patients: Success for Medicare Part D Walks in the Back Door
Hailed by politicians as long-awaited assistance for seniors and the disabled with the rising costs of prescription drugs, Medicare Part D primarily helps indigent and low-income patients. Moreover, poverty-level patients will find stable prices and versatility in obtaining prescription medications under Medicare D. For low-income patients using pharmacies of their choice-including hospital pharmacies, if they so choose, there are reduced transportation hassles and reduced associated expenses. Poverty-level patients with the additional Social Security subsidy have no deductible and no gaps in their coverage. However, two unintended, unforeseen circumstances occurred with the implementation of Medicare Part D: 1. The exodus of patients from hospital pharmacies and from central pharmacies (e.g., pharmacies serving a particular HMO plan) to neighborhood pharmacies lowered the volume of medications provided and stabilized a teetering and overwhelmed system of prescription drug provision; and 2. Many hospital pharmacies charge on a sliding scale, and the users of specialty medications (e.g., Zyprexa) with large copays under Medicare Part D found minimal costs and big savings at the low end of the sliding scale (for example, $5). The biggest successes for Medicare Part D truly came through an unintended back door and serve as an economic advantage for the poor.
Key words: Medicare Part D, prescription drugs, low-income subsidy, indigent patients, hospital pharmacies.

MEDICARE Part D, the product of Congress and the US Department of Health & Human Services, is the long-awaited prescription drug program intended to make it easier for recipients (seniors and the disabled) to obtain medications needed to maintain optimum health.1 Characterizations in the media of the indigent aged begging for their medications or doing without them were largely fallacious. Instead, low-income and indigent patients were the unintentional targets of Medicare drug reform that most of them did not need and sometimes even cost them more under the new prescription drug plan.

In concert with the Bush Administration's conservative agenda, the federal government effectively privatized the present system of public sector Medicare insurance by legislating drug provision by private sector Medicare Part D insurance companies (Medicare Part D HMOs). This effectively became a boon to both the insurance industry and pharmaceutical manufacturers. For the patients, their ability to navigate the "sea of choices" available with Medicare D and gain access to necessary medications still (i.e., even after Medicare Part D implementation) depends upon cost (see below), as well as socioeconomic status, educational level, age, and disability.

The Medicare Part D program was developed to replace the faltering but functional central pharmacy and outpatient hospital drug provision programs (that existed under local and state support using mostly sales tax revenue). Medicare Part D was intended to stabilize the prices lowincome patients pay for prescriptions, and that it did, but sometimes recipients pay more than before (i.e., depending on the plan and the medication). At the time of the legislation, central pharmacies or county hospitals already provided low-income and indigent patients with medications at extremely reduced prices. All formulary prescriptions, including high-cost specialty drugs, were provided to indigent patients for a standard fee of $5 each (the bottom of a sliding scale).

Interestingly enough, with all the hoopla over Medicare Part D, some of these patients may be able to return to their original hospital pharmacies (especially while under care at the hospital-whether for acute or chronic care). These patients may get their medications, including the more expensive brand name and specialty medications, for the previous costs (i.e., before Medicare D coverage). For example, under Medicare Part D, neighborhood pharmacies may charge $75 for the behavioral drug Zyprexa (see Figure 1) and $35 for the anti-lipid drug Niaspan. On the other hand, the hospital pharmacy, at the indigent level of the sliding scale, charges only $5 each for the exact same medications. However, the option of Medicare Part D offers patients (including the indigent) to return to the central or hospital pharmacies may not be widely known or even considered.

Filling prescriptions by low-income patients at the neighborhood pharmacy may continue due to the following reasons:

1. Patients are unaware that they can return to the county hospital pharmacies or that any money can be saved on their medications. (The amounts are quite significant with specialty drugs like Zyprexa.)

2. The convenience afforded by neighborhood pharmacies, with little travel time and no long waiting periods (in crowded hospital pharmacy waiting rooms) overwhelms any possible monetary savings.

3. The confusion and bureaucratic red tape in the Medicare Part D plans and the lack of close personal scrutiny of the cost of multiple prescriptions may mask the recipient's total expenses.

This lack of awareness of the cost of medications under Medicare Part D may have several possible reasons. Oversight of costs by patients may be due to payment by credit card rather than cash. (In today's financial climate, even indigent and low-income patients often have credit cards.) In addition, the generally less educated low-income patient may be overwhelmed by all the accompanying paperwork involved with filling a prescription at a neighborhood pharmacy. This may hide the real costs of patients' prescription medications under Medicare Part D. Furthermore, most Medicare Part D patients are unaware of how to change prescription plans (i.e., they expect a difficult process) and therefore accept the costs as a matter of course. In addition, by significantly lowering costs, the flood of new generic medications coming into the market helped stabilize provision of prescription medications by the Medicare Part D program and the central pharmacies/county hospitals.

The above conditions were all favorable for the county hospitals, as a financial crisis and a subsequent sales tax increase may have been averted by effectively shifting the burden for prescription drug provision to the private sector (i.e., Medicare D HMOs). The initial exodus of Medicare D recipients to neighborhood pharmacies financially unburdened the strapped county hospitals that were operating pharmacies at a loss. Subsequently, these hospitals held the line on costs and continued the policy of offering pharmacy services to their patients based on a sliding scale according to the patients' ability to pay.

In the early days of Medicare Part D, the Social Security Administration2 offered a subsidy to help defray the costs of medications for indigent and low-income patients. Most of these poverty-level patients qualified for the low-income subsidy that served to expand insurance coverage with Medicare Part D. However, patients found the eligibility and application process to be quite "beneficiary unfriendly."3

All Medicare Part D recipients, including those with the low-income subsidy, are required to pay the monthly insurance premium-a "surprise" and unexpected expense for most beneficiaries. Even recipients without the subsidy and in the "donut hole" coverage gap, while receiving effectively no coverage from the prescription drug plan, are required to pay the monthly premium. In addition, many patients did not understand that the subsidy had significant benefits like eliminating the "donut hole" coverage gap, canceling the deductible, and lowering overall costs of medications to the consumer.4 With a limited enrollment period, many patients eligible for the low-income subsidy were simply unaware of the benefit, did not bother to apply, or did not apply in time.5

Another major difficulty with the lowincome subsidy was that the enrollment rolls were purged yearly on January 1st, with many unaware but still-eligible patients losing the subsidy by failing to reapply. The National Senior Citizens Law Center6 estimates that 60 percent of all enrollees in Medicare Part D receive, or are eligible to receive, the low-income subsidy. However, the Law Center estimates that at least one third of those eligible for the low-income subsidy are not receiving the benefit.

Conclusions

Medicare Part D, fraught with too many easily misunderstood choices and options, sometimes requires the advice of an attorney during the application process to determine the best plan for a patient's needs. But low-income patients usually do not seek advice, and those who do often cannot comprehend the information provided by pharmacists, publications, the Medicare Part D Web site, or the telephone "Medicare Help Line." To choose the best plan, applicants must wade through a plethora of choices and options, taking into account their particular prescribed medications, along with the multiple plan options from each individual provider.

Considering the effects of Medicare Part D upon indigent and low-income individuals, consigning too much choice and needless layers of bureaucracy to generally the most impaired, friable, and illiterate group of patients may interfere with obtaining prescriptions and maintaining drug treatment regimens. In addition, the Medicare Part D program could be confusing in its initial implementation, sometimes even requiring a telephone call from the pharmacist to the provider to initiate individual coverage.

The actual coverage provided by Medicare Part D insurance plans to recipients with modest or higher incomes is actually quite limited considering the monthly premium, the "donut hole" coverage gap, and the limitations of the provider's formulary of available medications. In comparison, low-income and indigent patients in this brave new world of privatized prescription coverage receive highly effective and expensive drugs with policy premiums and copayments dependent on the content of formularies, availability of generics, manufacturer drug costs, and the policies of the particular Medicare Part D insurance provider.

Poverty-level patients still may find themselves paying more for brand-name and specialty drugs under Medicare Part D (Table 1). All this change and constraint upon prescription drug provision and insurance coverage occurs concurrently with profits soaring in the insurance and pharmaceutical industries.

[Reference]
REFERENCES
1. Centers for Medicare & Medicaid Services (2007), Medicare & You, Publication No. CMS-10050-28, Baltimore: USDHHS.
2. Social Security Administration (2006), "Medicare Prescription Drug Assistance: Important Information," Document 0000137207, Birmingham, AL: Southeastern Program Service Center.
3. National Senior Citizens Law Center (2006), "Health Issues: Medicare Part D-The New Prescription Drug Bill: How Medicare Part D Affects Low-Income Seniors and People with Disabilities," http://www.nsclc.org/areas/ medicare-part-d, accessed Sept. 28, 2006.
4. American Academy of Family Physicians (2006), "R. Graham Center One-Pager: Medicare Part D, Who Wins, Who Loses?" American Family Physician, vol. 73 no. 3, http:// www.aafp.org/afp/20060201/graham1.html, accessed Feb. 25, 2006.
5. D. Havrda, B. Omundsen, W. Bender, and M. Kirkpatrick (2005), "Impact of the Medicare Modernization Act on Low-Income Persons," Annals of Internal Medicine, vol. 143 no. 8: 600-608.
6. Supra n.3.
[Author Affiliation]
Paul J. Flaer, EdD, DDS, MPH, is a Doctorate Fellow at Florida International University. He provides charity dental work for disadvantaged populations in Miami, Florida. He is presently working on a PhD at the Robert Stempel School of Public Health at Florida International University.
Mustafa Z. Younis, DrPH, MA, MBA, Department of Health Policy & Management, Jackson State University. His research interests include health economics policy and finance.
Robert M. Malow, PhD, is a Professor in the Florida International University, Robert Stempel School of Public Health, and is the Director of the AIDS Prevention Program, the umbrella for several federally funded studies that focus on establishing effective interventions for ensuring the implementation of promising HIV/AIDS interventions for high-risk populations.
J Health Care Finance 2008;34(3):1-5
© 2008 Aspen Publishers, Inc.

Smiling does a body good

Democracy Now Livestream